Madrigal Pharmaceuticals Inc’s filing revealed that its Senior VP, Chief Pharma Dev. Waltermire Robert E. unloaded Company’s shares for reported $0.53 million on Jun 14 ’24. In the deal valued at $280.00 per share,1,900 shares were sold. As a result of this transaction, Waltermire Robert E. now holds 5,500 shares worth roughly $1.34 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Waltermire Robert E. sold 2,000 shares, generating $570,000 in total proceeds. Upon selling the shares at $285.00, the Senior VP, Chief Pharma Dev. now owns 5,500 shares.
Before that, Waltermire Robert E. sold 1,036 shares. Madrigal Pharmaceuticals Inc shares valued at $239,668 were divested by the Senior VP, Chief Pharma Dev. at a price of $231.34 per share. As a result of the transaction, Waltermire Robert E. now holds 5,500 shares, worth roughly $1.34 million.
Cantor Fitzgerald initiated its Madrigal Pharmaceuticals Inc [MDGL] rating to a Neutral in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid June with a ‘”an Outperform”‘ rating. BofA Securities began covering MDGL with “an Underperform” recommendation on April 22, 2024. B. Riley Securities revised its rating on March 15, 2024. It rated MDGL as “a Neutral” which previously was an “a Sell”.
Price Performance Review of MDGL
On Tuesday, Madrigal Pharmaceuticals Inc [NASDAQ:MDGL] saw its stock jump 0.64% to $243.64. Over the last five days, the stock has lost -8.60%. Madrigal Pharmaceuticals Inc shares have risen nearly 5.30% since the year began. Nevertheless, the stocks have risen 42.12% over the past one year. While a 52-week high of $299.98 was reached on 03/15/24, a 52-week low of $119.76 was recorded on 02/09/24. SMA at 50 days reached $271.44, while 200 days put it at $232.01.
Levels Of Support And Resistance For MDGL Stock
The 24-hour chart illustrates a support level at 241.56, which if violated will result in even more drops to 239.47. On the upside, there is a resistance level at 245.67. A further resistance level may holdings at 247.69. The Relative Strength Index (RSI) on the 14-day chart is 39.08, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -22.49, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.29%. Stochastics%K at 23.54% indicates the stock is a holding.
How much short interest is there in Madrigal Pharmaceuticals Inc?
A steep rise in short interest was recorded in Madrigal Pharmaceuticals Inc stocks on
The most recent change occurred on March 06, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $382 price target.
